UNIVERSITY OF MIAMI Curriculum Vitae 1. Date: 9/2014 I. PERSONAL 2. Name: Niramol Savaraj 3. Office Phone: (305)575-3143 6. Current Academic Rank: Research Professor 7. Primary Department: Medicine 8. Citizenship: U.S. II.HIGHER EDUCATION Mahidol University, Bangkok, Thailand B.S. 1970 Mahidol University, Bangkok, Thailand M.D. 1973 American Board of Internal Medicine l976 American Board of Medical Oncology l979 American Board of Hematology l980 Washington D.C. 7950 - Renewal No. 45l2 State of Texas F5367 III.EXPERIENCES
Transcript
UNIVERSITY OF MIAMI
Curriculum Vitae
1. Date: 9/2014
I. PERSONAL
2. Name: Niramol Savaraj
3. Office Phone: (305)575-3143
6. Current Academic Rank: Research Professor
7. Primary Department: Medicine
8. Citizenship: U.S.
II.HIGHER EDUCATION
Mahidol University, Bangkok, Thailand B.S. 1970
Mahidol University, Bangkok, Thailand M.D. 1973
American Board of Internal Medicine l976
American Board of Medical Oncology l979
American Board of Hematology l980
Washington D.C. 7950 - Renewal No. 45l2
State of Texas F5367
III.EXPERIENCES
1985–present Attending physician, Section of Hematology/Oncology, Veterans Administration Medical Center, Miami, FL.
2004-present Research Professor, University of Miami School of Medicine
2
Savaraj - 2
Graduate faculty; Cancer Cell Biology. University of Miami Miller School of Medicine
1993-2003 Adjunct Professor, University of Miami Miller School of medicine
l985-1992 Associate Professor of Oncology, University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL.
9/1985 Associate Professor of Medicine, Department of Chemotherapy Research, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, TX.
l98l-l985 Assistant Internist and Assistant Professor of Medicine, Department of Developmental Therapeutics, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, TX.
l980-l98l Faculty Associate, Department of Developmental Therapeutics, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, TX.
l979 Consultant in Oncology, Veterans Administration Medical Center, Miami, FL.
l979 Instructor, Department of Oncology and Comprehensive Cancer Center for the State of Florida, University of Miami School of Medicine, Miami, FL.
IV. PUBLICATIONS
Scientific Articles in Referred Journals
1. Savaraj N, Allen LM, Sutton C, and Troner M: Immunology modification of adriamycin cardiotoxicity. Res Commun Chem Path and Pharmacol 29:549-559, l980.
2. Savaraj N, and Troner MB: Aminoglutethimide in the treatment of metastatic breast cancer. Med and Ped Oncol 8:25l-263, l98l.
3. Lian EC-Y and Savaraj N: Effect of platelet inhibitors on the platelet aggregation induced by plasma from patients with TTP. Blood 58:354-359, l98l.
2
3
Savaraj - 3
4. Valdivieso M, Bedikian AY, Burgess M, Savaraj N, Jeffers W, and Bodey GP: Phase I clinical study of dihydroxyanthracenidione administered on a 5-day intravenous schedule. Can Treat Rpt 65:84l-844, l98l.
5. Savaraj N, Lu K, Valdivieso M, Burgess MA, Umsawasdi T, Benjamin RS, and Loo TL: Clinical pharmacokinetics of l,4'-Dihydroxy-5,8 Bis (2-(2-Hydroxyethyl) (amino)-ethyl)amino)9,l0-Anthracededione. Clin Pharm and Thera 31:32l-3l6, l982.
6. Savaraj N, Lu K, and Loo TL: Clinical pharmacology of Mitoxantrone. Can Chemo Pharmacol 8:ll3-ll7, l982.
7. Savaraj N, Lu K, Feun LG, Leavens ME, Stewart DJ, Benjamin RS, and Loo TL: Intracerebral penetration and tissue distribution of AZQ. J of Neuro-Onc l:l5-l9, l983.
8. Feun LG, Stewart DJ, Leavens ME, Burgess MA, Savaraj N, Benjamin RS, and Bodey GP: A phase II trial of PCNU in primary malignant brain tumors. J of Neuro-Onc l:45-48, l983.
9. Lu K, Savaraj N, Huang MT, Moore D, and Loo TL: High performance liquid chromatography (HPLC) of the new antineoplastic CL 2l6-942 Bisantrene. J of Liquid Chrom 5(7):l323-l328, l982.
10. Feun LG, Stewart DJ, Maor M, Leavens M, Savaraj N, Burgess MA, Yung WKA, and Benjamin RS: A pilot study of CDPP and radiation therapy in high grade astrocytoma. J of Neuro-Onc l:l09-ll3, l983.
11. Feun LG, Savaraj N, Lu K, Guo ZG, Raulston G, Benjamin RS, and Loo TL: The Benzoquinone (AZQ, NSC- l82986) by intracarotid or intravenous administration in beagles. J of Neuro-Onc l:2l9-224, l983.
12. Loo TL, Liu J, Lu K, and Savaraj N: Clinical pharmacokinetics of 5-Methyltetrahydrohomofolate. Cancer Res 43:92l-924, l982.
13. Lu K, Savaraj N, Yap BVS, Bedikian AY, Feun LG, and Loo TL: Clinical Pharmacology of 2-5'-Diazinidinyl-3-6-Biscarboethoxy-amino-l,4-Benzoquinone (AZQ). Eur J Can and Clin Oncol l9:603-606, l983.
14. Guo ZG, Savaraj N, Feun LG, Lu K, Stewart DJ, Luna M, Benjamin RS, and Loo TL: Tumor penetration of AMSA in man. Can Invest l:475-478, l983.
15. Feun LG, Wallace S, Stewart DI, Chuang VP, Leaven ME, Burgess MA, Savaraj N, Benjamin RS, Young SE, Tang RA, Handel S, Mavligit G, and Field WS: Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent, malignant brain tumors. Cancer 54:794-799, l984.
3
4
Savaraj - 4
16. Wright KC, Charnsangavej C, Wallace S, Chuang VP, Savaraj N.: Regional isolation-perfusion: an experimental percutaneous approach tested and compared with arterial occlusion-infusion. Cardiovasc Intervent Radiol. 1984;7(6):294-8.
17. Feun LG, Yung WKA, Leavens ME, Burgess MA, Obbens EAMT, Bedikian AY, Savaraj N, Stewart DJ, Benjamin RS, Field WS, and Bodey GP: A phase II trial of 2,5-Diaziridinyl 3,6-BIS (Carboetnoxy l,4 Benzoquinone (AZQ, NSC l82986) in recurrent primary brain tumor. J Neuro-Onc 2:13-l7, l984.
18. Feun LG, Savaraj N, Bodey GP, Lu K, Yap BS, Ajani JA, Burgess MA, Benjamin RS, McKelvy E, and Krakoff I: Phase I study of tricyclic nucleoside phosphate using a 5-day continuous infusion schedule. Cancer Res 44:3608-36l2, l984.
19. Feun LG, Wallace S, Yung WKA, Lee Y-Y, Leavens ME, Moser R, Savaraj N, Burgess MA, et al: Phase I trial of intracarotid BCNU and cisplatin in patients with malignant intracerebral tumors. Cancer Drug Delivery l:239-245, l984.
20. Stewart DJ, Zhengang G, Lu K, Savaraj N, Feun LG, Luna M, Benjamin RS, Keating MJ, and Loo TL: Human tissue distribution of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (NSC l4l549, AMSA). Cancer Chemother Pharmacol 12:ll6-ll9, l984.
21. Lu K, Savaraj N, and Loo TL: Pharmacological disposition of l,4-dihydroxy-5-8 Bis 2 (2-hydroxyethyl)amino ethyl amino-9,l0-anthracedendione dihtdrochloride in the dog. Cancer Chemother Pharmacol 13:63-66, l984.
22. Obbens EAMT, Feun LG, Leavens ME, Savaraj N, Stewart DJ, and Gutterman JN: Phase I clinical trial of intralesional and intraventricular leukocyte interferon for intracranial malignancies. J of Neuro-Onc 3:6l-67, l985.
23. Feun LG, Savaraj N, and Ozarda AT: Cisplatin in medulloblastoma with extracranial metastasis: A case report. Cancer Treat Rpts 68:l307-l309, l984.
24. Feldman LD, Feun LG, Benjamin RS, Plager C, Papadopoulos N, Savaraj N, Burgess MA, and Bodey GP: A phase II trial of PCNU in patients with malignant mesothelioma and central nervous system metastases. Am J of Clin Onc 8:215-217, l985.
25. Feun LG, Yung WKA, Stewart DJ, Savaraj N, and Bodey GP: Phase II trial of methyl-GAG in malignant primary brain tumors. Cancer Treat Rpts 69:329-330, l985.
4
5
Savaraj - 5
26. Lu K, Savaraj N, and Newman RA: Liquid chromatographic separation and quantitation of benzisoquinolinedine (NSC-308847, nafidimide) from biological fluids. J. of Chromat. 345(2):408-412, l985.
27. Savaraj N, Feun LG, Lu K, Wallace S, Fields WS, and Loo TL: Clinical pharmacology of intracarotid etoposide. Cancer Chemo Pharm l6:292-294, l986.
28. Savaraj N, Lu K, Feun LG, Burgess MA, and Loo TL: Comparison of CNS penetration, tissue distribution and pharmacology of VP l6-213 by intracarotid and intravenous administration in dogs. Cancer Investigation 5(1):11-6, 1987.
29. Savaraj N, Lu K, Dimery I, Feun LG, Burgess M, Keating M, and Loo TL: Clinical pharmacology of homoharringtonine. Cancer Treat Rep 70:l403-l407, l986.
30. Lu K, Savaraj N, Yap B-S, Feun LG, Umsawasdi T, and Loo TL: Clinical pharmacokinetics of 9, l0k-anthracenedi-carboxaldehyde-bis-[(4,5, dihydro-lH-imidazole-2-yl)Hydrazone]k-dihydrochloride. Canc Chemo Pharm l6:l56-l59, l986.
31. Lu K, Savaraj N, Kavanagh J, Feun LG, Burgess M, Bodey GP, and Loo TL: Clinical pharmacology of 4-demethoxydaunorubicin DMDR. Cancer Chemother Pharmacol l7:l43-l48, l986.
32. Pasterz R, Savaraj N, and Burgess M: Analysis of prognostic factors in patients with metastatic carcinoma of unknown primary. J of Clin Oncology 4:l652-l657, l986.
33. Kavanagh JJ, Yeung K, Savaraj N, and Krakoff I: Phase I clinical evaluation and intravenous 4-demethoxydaunorubicin. Eur J Cancer Clin Oncol 2l:ll87-ll89, l985.
34. Savaraj N, Feun L, Lu K, Leavens M, Moser R, and Loo TL: Central nervous system (CNS) penetration of homoharringtonine. J of Neuro Oncol 5:77-8l, l987.
35. Feun L, Lee YY, Yung W-KA, Savaraj N, and Wallace S: Intracarotid VP-l6 in malignant brain tumors. J of Neuro Oncol 4:397-40l, l987.
36. Khorsand J, Katz RL, and Savaraj N: Malignant carcinoid of the pancreas: A cytologic, ultrastructural, and immunocytochemical study of a case diagnoised by fine-needle aspiration of a supraclavicular node metastasis. Diag Cytopath 1987 Sep;3(3):222-7.
37. Vogel CL, Gorowski, E, Davila E, Eisenberger M, Kosinski J, Agarwal RP, and Savaraj, N: Phase I clinical trial and pharmacokinetics of weekly ICRF - l87 (NSC l69780): Infusion in patients with solid tumors. Invest New Drugs. 1987;5(2):187-98.
5
6
Savaraj - 6
38. Wright KC, Stephens LC, Wallace S, Savaraj N, and Feun LG: Experimental combination chemotherapy: Intracarotid versus intravenous administration of azuridinylbenzoquinone BCNU and cisplatin in dogs. Chemotherapy 33:438-444, 1987.
39. Lu K, Savaraj N, Feun LG, Zhengang G, Umsawasdi T, and Loo TL: Pharmacokinetics of homoharringtonine in dogs. Cancer Chem Pharm 21:139-142, 1988.
40. Feun LG, Savaraj N, Legha SS, Silva EG, Benjamin RS, Burgess MA: Chemotherapy for metastatic merkel cell carcinoma. Cancer 62:683-685, 1988.
41. Clayton C, Logothetis C, Savaraj N, Fritsche H, Gietner A, and Samuels M: The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients. J Clin Pharmacol 28:714-718, 1988.
42. Savaraj N, Ling J, Lu K, Feun LG, and Hsu TC: Genotoxicity of 1H-Benz[DE] isoquinoline-1 3(2H0-Dione, 5 Amino-2-[2-(Dimethylamino) ethyl] (BIDA) in human lymphocytes. Cancer Investigation 7:117-121, 1989.
43. Hussein AM, Savaraj N, Feun LG, Ganjei P, and Donnelly E: Carcinomatous meningitis from transitional cell carcinoma of the bladder: Case report. J Neuro Onc 7:255-260, 1989.
44. Lampidis T, Castello C, Gliglio A, Pressman B, Viallet P, Trevorrow K, Valet G, Tapiero H, and Savaraj N: Relevance of chemical change of Rhodamine dyes to multidrug resistance. Biochem Pharm 38:23, 4267-4271, 1989.
45. Hussein AM, Feun LG, Savaraj N, East D, Hussein D. Carcinoid tumor presenting as central nervous system symptoms. Case report and review of literature. Amer Jour of Clin Onc 13(1):251-5, 1990.
46. Lampidis T, Savaraj N, Valet K, Trevorrow K, Fourcade A, and Tapiero H: Relationship of chemical change of anticancer agents to increased accumulation and cytotoxicity in cardiac and tumor cells: Relevance to multidrug resistance. J of Cellular Pharm 1:16-22, 1990.
47. Serafini AN, Kotler J, Feun LG, Dewanjee M, Savaraj N, Robinson D, Sfakianaki, Abrams P, Goodwin D, and Nelp W: Technetium-99m labeled monoclonal antibodies in the detection of metastatic melanoma. Clin Nucl. Med. 14(8):580-7, 1989.
48. Sridhar KS, Samy TSA, Koch G, Agarwal RP, Duncan RC, Ganz WI, Benedetto P. Feun LG, Savaraj M, Gross J, Krishan A, and Zubrod CG:
6
7
Savaraj - 7
Phase I study of 4'0' - Tetra hydropyranyl adriamycin. Cancer 1990 Nov 15;66(10):2082-91 .
49. Feun LG, Maor M, Stewart PJ, Leavens ME, Young WK, Savaraj N, Burgess MA, Benjamin RS. Fields WS, and Bodey GP: A pilot study of PCNU and cranial radiation therapy in the treatment of patients with malignant gliomas. Oncology 47:389-392, 1990.
50. Feun LG, Savaraj N, Landy H, Levin H, Lampidis T: Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors. J Neuro Onc 9:159-163, 1990.
51. Gliglio A, Savaraj N, Cantello C, Tapiero H, White L, Kalondis D, and Lampidis TJ: Comparative effects of memogaril and adriamycin on cardiac and multidrug resistant tumor cells. J Cellular Pharm 1:124-128, 1990
52. Feun LG, Albores S, and Savaraj N: Osteosarcoma arising adjacent to a longstanding ameloblastoma. Oral Surgery, Oral Medicine, and Orial Pathology, 71-79, 1991.
53. Ardalan B, Stridhar K, Reddy R, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Livingstone A.: Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. Int J Radiat Oncol Biol Phys. 1992;22(3):511-4.
54. Ardalan B, Sridhar KS, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Fodor M, Livingstone A.: A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. Cancer. Sep 15;68(6):1242-6, 1991.
55. Sridhar KS, Hussein AM, Benedetto P, Waldman SM, Feun LG, Savaraj N, Richman SP, Ardalan B, Desai P.: Phase II trial of mitoxantrone in head and neck carcinoma.Am J Clin Oncol. Aug;14(4):298-304, 1991.
56. Feun LG and Savaraj N: Detection of occult bone metastases by magnetic resonance imaging. J Fl Med Assoc 88:881-883, 1990.
57. Feun LG, Gonzalez R, Savaraj N, Hanlon H, Collier M, Robinson WA, and Clendennin NJ: Phase II trial of piritrexim (301u, 74, PTX) capsules in metastatic melanoma using prolonged, low-dose administration. JCO 9:464-467, 1991.
58. Feun LG, Savaraj N, Lee YY, Landy H, Martinez-Prieto J, Charnsangavej C, Post D, Lee KF, Wallace S, Bowen B, Kochan JP, and Yung WKA: A pilot clinical and pharmacokinetic study of intracarotid cisplatin and bleomycin. Selective Cancer Therapeutics 1991 Spring;7(1):29-36.
7
8
Savaraj - 8
59. Lampidis TJ, Kolonias D, Savaraj N, and Rubin R: Cardiostimulatoru and anti-arrhythmic activity of tubulin-binding agents. Proc Natl Acad Sci U.S.A. 89:1256-1260,1992.
60. Trevorrow KW, Valet G, Tapiero H, Savaraj N, and Lampidis TJ: Carboxylic ionophores increased rhodamine 123 retention in multidrug resistant frienf leukemic cells with increased MDR1 gene expression. J Cell Pharmacol 4:29-36, 1991.
61. Feun LG, Savaraj N, Benedetto P, Sridhar K, Hanlon J, Collier M. Richman S, and Clendennin NJ: Phase I trial of piritrexim (BW 301, PTX) capsules using prolonged low-dose administration. JNCI 83:51-55, 1991.
62. Ardalan B, Sridhar K, Benedetto P, Richman S, Waldman S, Morrell L, Feun LG, Savaraj N, and Livingstone A: Phase I and II study of high-dose 5-Fluorouracil and high dose of Leucovorin with lose-dose PALA in patients with advanced malignancies. Cancer. 1991 Sep 15;68(6):1242-6 (In press).
63. Savaraj N, Feun, Lu K, Wang C, and Loo TL: Pharmacology of intrathecal VP-16-213 in dogs. J. Neuro-Onc. 13:211-215,1992.
64. Moore M, Donnelly, Feun LG, and Savaraj N: Successful Therapy of peritoneal mesothelioma with intraperitoneal chemotherapy alone Am. J. of Clin. Onc. 1992 Dec;15(6):528-30.
65. Brouty-Boye D, Kolonias D, Savaraj N, and Lampidis TJ: Smooth muscle actin expression in cultureed cardiac fibroblasts of new born rat In Vitro Cell Del. Biol. 28A:1-4, 1992.
66. Feun LG, Savaraj N, Bujnoski J, Nadeem S.: Spinal cord compression produced by osteomyelitis mimicking spinal epidural metastasis.Am J Clin Oncol. Apr;15(2):174-9, 1992.
67. Dellinger M, Pressman B, Higgenson C, Kolonias D, Savaraj N, and Lampidis TJ: Structure function activity of simple lipophilic cations in multidrug resistant cells. Cancer Research 52:6385-6389, 1992.
68. Savaraj N, Feun L, Blyden G, et al: A pilot clinical and pharmacological study of intra-arterial infusion of Thiotepa. Cancer Biother. 8(1):38-42,1993.
69. Feun LG, Blyden G, Yrizarry J, Dorvil M, Waldman S, Benedetto P, Donnelly E, Curtas J, George M, and Savaraj N: Clinical and Pharmacological Study of Intrahepatic Artery Infusion of Thiotepa. Cancer Biother. 8(1):43-48, 1993.
70. Cheng CC, Dong Q, Liu LF, Chen AY, Savaraj N, and Chou TC: Design
8
9
Savaraj - 9
of Antineoplastic Agents on the basis of the "2-Phenylnaphthalene-type" Structure Pattern II Synthesis and biological activity studies of Benzo b naphtho 2.3-d furan-6,11- dione derivatives. J. of Med. Chem. 1993.
71. Hsu TC, Savaraj N, Trizna Z, Feun L, Furlong C, Schantz SP, Shirley L, and Shen DY: Cytogenetic studies on the genotoxicity of 4-nitroquinoline-1-oxide on human cells in vitro. Int. J. of Onc. 3:823-826, 1993.
72. Hsu TC, Feun L, Trizna Z, Savaraj N, Shirley LR, Furlong CL, Schantz SP, Neber RS, Shen TJ, and Kucuk O: Differential sensitivity among human subpopulations in response to 4-nitroquinline-1-oxide and to bleomycin. Int. J. of Cancer 3:827-830, 1993.
73. Sridhar KS, Thurer RJ, Markoe AM, Chatoor HT, Fountzilas G, Raub WJ, Savaraj N, Beattie EJ.:Multidisciplinary approach to the treatment of locally and regionally advanced non-small cell lung cancer: University of Miami experience. Semin Surg Oncol. Mar-Apr;9(2):114-9, 1993.
74. Savaraj N, Wu CJ, Lampidis TJ, Chua L, and Feun L: In vitro cytotoxicity of U-73975 in multidrug resistant and cisplatin resistant cells. J. of Cell. Pharm. 2:103-106, 1994.
75. Savaraj N, Lampidis T, Zhao ZY, Wu CJ, Teeter LD, and Kuo MT: Multidrug resistant cells selected with different drugs is associated with overproduction of different P-glycoproteins. Cancer Investigation 12(2):138-144, 1994.
76. Lampidis TJ, Kolonias D, Savaraj N, and Rubin RW: The effects of tubulin-binding agents on cardiac cell contractility in vitro. J. Cell Pharmacol. 3:1-2, 1992.
77. Zhao JY, Savaraj N, Song r, Priebe W, and Kuo MT: Overexpression of P-Glycoprotein but not its mRNA in Multidrug Resistant cells selected with Hydroxyrubicin Anticancer Res. 14:1735-1742,1994.
78. Feun LG, Reddy KR, Yrizarry JM, Savaraj N, Guerra JJ, Purser RK, Waldman S, Levi JU, Moffat F, Morrell L, Livingstone AS, Ardalan B, and Benedetto P. A phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer. Am J Clin Oncol 17:405-410, 1994.
79. Feun LG, Savaraj N, Hung S, Reddy R, Jeffers L, Benedetto P, Livingstone AS, Ardalan B, Levi JU, Parker T, and Schiff ER. A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma. Am J Clin Oncol 17:393-395, 1994.
9
10
Savaraj - 10
80. Feun LG, Savaraj N, Benedetto P, Waldman S, Collier M, and Clendennin NJ. Oral piritrexim in advanced bladder cancer: An effective drug after progression on MVAC chemotherapy? Am J Clin Oncol, 17 (5):448-451, 1994.
81. Feun LG, Raub WA, Jr., Duncan RC, Moffat F, Savaraj N, Nemeth A, Markoe A, and Trapido E. Melanoma in a Southeastern Hispanic Population. Cancer Detection and Prevention 18 (2):145-152, 1994.
82. Feun LG, Robinson WA, Savaraj N, Gonzalez R, Liebmann A, Offenhauser K, and Clendennin NJ. Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma. Am J Clin Oncol 17:448-451, 1994.
83. Feun LG, Savaraj N, and Landy JH. Drug resistance in brain tumors. J Neuro-Oncol 20:165-176, 1994.
84. Podack ER, Zhao D, Ohe Y, Nishio M, Cassileth PA, Roderick JF, Spielman J, and Savaraj N: Gene therapy for small cell lung carcinoma and demonstration of tumor specific CTL restricted by HLA A2. Contemporaneous Publication of the Proceedings of the XVI International Cancer Congress, pp 1-4, 1994.
85. Brouty-Boye D, Kolonias D, Wu CJ, Savaraj N, and Lampidis TJ: Relationship of Multidrug resistance to Rhodamine-123 selectivity between carcinoma and normal epithelial cells: Taxol and Vinblastine modulate drug efflux. Cancer Res.55:1633-1638,1995.
86. Cassileth PA, Podack E, Sridhar K, Savaraj N, Hanlon J.Phase: I study of transfected cancer cells expressing the interleukin-2 gene product in limited stage small cell lung cancer.Hum Gene Ther. Mar;6(3):369-83, 1995.
87. Feun LG, Robinson WA, Savaraj N, Gonzalez R, Liebmann A, Offenhauser K and Clendennin NJ. Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma. Am J Clin Oncol 18(6):488-490, 1995.
88. Feun LG, Savaraj N, Solomon J, Liebmann A and Hurley J: Phase II trial of mitoxantrone and cisplatin in advanced non-small cell lung cancer. Am J Clin Oncol, 19(2):190-192, 1996.
89. Xu J, Tyan T, Cedrone E, Savaraj N and Wang N: Detection of 11Q13 amplification as the origin of a homogeneously staining region in small cell lung cancer by chromosome microdissection. Genes, Chromosomes & Cancer, 17(3):172—178, 1996.
90. Savaraj N, Wu CJ, Xu R, Feun L, Lampidis TJ and Kuo MT: Quantitative Multidrug Resistance Associated Protein (MRP) Gene Expression by Competitive Reverse-Transcriptase Polymerase Chain Reaction. Cellular Pharmacology, 3:349—354, 1996.
10
11
Savaraj - 11
91. Podack ER, Nishlo M, Savaraj N, Spielman J, Casselith PA, Heike Y, Ohe Y, Saijo N: Induction and targeting of tumor—specific CTL. J Clin Biochem & Nutrition, 21(1):85—86, 1996.
92. Feun LG, Savaraj N, Moffat F, Robinson D, Liebmann A, Hurley J, Raub, Jr., W. and Richman S. Phase II trial of recombinant alpha-interferon (Intron) with BCNU, Cisplatin, DTIC, and Tamoxifen in advanced, malignant melanoma Melanoma Res. 1995 Aug;5(4):273-6.
93. Savaraj N, Wu CJ, Xu R, et al: Multidrug Resistant Gene Expression in Small Cell Lung Cancer. American Journal of Clinical Oncology, 20(4):398-483, 1997.
94. Lertratanangkoon K, Savaraj N, Scimeca JM, Thomas ML: Glutathione depletion-induced thymidylate insufficiency for DNA repair synthesis. Biochem & Biophy Res Comm, 234(2):470—475, 1997.
95. Lampidis TJ, Kolonias D, Podona T, Israel M, Safa AR, Lothstein L, Savaraj N, Tapiero H and Priebe W: Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. Biochemistry, 36(9):2679—2685, 1997.
96. Lampidis TJ, Shi YF, Calderon CL, Kolonias D, Tapiero H, Savaraj N: Accumulation of simple organic cations correlates with differential cytotoxicity in multidrugresistant and —sensitive human and rodent cells. Leukemia, 11(7):1156—1159, 1997.
97. Savaraj N, Xu R, Landy H, Lai 5, Sternau L, Solomon J, Wu CJ, Lampidis T and Feun LG: Comparison of topoisomerase I and II expression in primary brain tumor and lung cancer. Oncology Rep., 4:857—861, 1997.
98. Lertratanangkoon K, Wu CJ, Savaraj N and Thomas M: Alterations of DNA methylation by glutathione depletion. Cancer Letters, 120:149—156, 1997.
99. Kuo MT, Bao J, Furuichi M, Yamane Y, Gomi A, Savaraj N, Masuzawa T, Ishikawa T: Frequent co-expression of MRP/GS-X pump and —glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues. Biochem Pharmacol, 55(5):605-615, 1998.
100. Priebe W, Krawczyk M, Kuo MT, Yamane Y, Savaraj N, Ishikawa T: Doxorubicin— and daunorubicin—glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Biochem Biophys Res Commun, 247(3):859-863, 1998.
101. Chang HX, Chou TC, Savaraj N, Liu LF, Yu C, Cheng CC: Design of antineoplastic agents based on the “2-phenylnaphthalene-type” structural pattern. 4. Synthesis and biological activity of 2-
11
12
Savaraj - 12
chloro-3-(substituted phenoxy)-1, 4-naphthoquinones and related 5,8-dihydroxy-1, 4-naphthoquinones. J Med Chem, 42(3):405-408, 1999.
102. Kolonias D, Podona T, Savaraj N, Gate L, Cossum P, Lampidis TJ: Comparison of annamycin to adriamycin in cardiac and MDR tumor cell systems. Anticancer Res, 19(2A):1277-83, 1999.
103. Yamzaki K, Spruill G, Rhoderick J, Spielman J, Savaraj N, and Podack ER. Small cell lung carcinoma express shared and private tumor antigen presented by HLA-A1 or H. Cancer Res. 15:4642-50, 1999.
104. Feun LG, Reddy KR, Scagnelli T, Yrizarry JM, Guerra JJ, Russell E, Schawatz M, Savaraj N, Livingstone AS, Levi JU, Jeffer J, Ardlan B and Schiff ER. A phase I study of chemoembolization with cisplatin, thiotepa, and liiodol for primary and metastatic liver cancer. Am J Clin Oncol 22:375-80, 1999.
105. Feun LG, Savaraj N, Hurley J, Marini A, and Lai S. A clinical trial of intravenous viorebine tartrate plus tamoxifen in the treatment of patients with malignant melanoma. Cancer 1:585-8, 2000.
106. Hu YP, Moraes C, Savaraj N, Priebe W, and Lampidis TJ. Tumor Cells: A model for studying whether mitochondria are target for Rhodamine 123, Doxorubicin and other drugs. Biochem Pharmacol. 2000 Dec 15;60(12):1897-905.
107. Zou JY, Howard L, Feun L, Xu R, Lampidis TJ, Wu CJ, Furst AJ and Savaraj N. Correlation of unique 220 kd protein with vitamin D sensitivity in glioma cells. Biochem Pharmacol. 2000 Nov 1;60(9):1361-5.
108. Liu H, Hu YP, Savaraj N, Priebe w, Lampidis TJ. Hypersensitozation of tumor cells to glycolytic inhibitors. Bicochemistry: 40: 5542-7, 2001.
109. Shigeru T, Hitoshi U, Sinicrope FA, Sakatani T, Sugumura K, Makino M, Ito H, Savaraj N, Kaibara N, and Kuo MT: Expression of heavy subunit of glutamylcysteine synthetase in human colorectal cancer. Int. J. Cancer 97:21-27.2002
110. Lin-Lee YC, Tatebe S, savaraj N, Ishikawa T, and Kuo M.T. Differential sensitivities of the MRP gene family and gamma glutamylcystenine synthetase to prooxidants in human colorectal carcinoma cell lines with different p-53 status. Biochem. Pharmacol.1:61 555-563, 2001
111. Feun L, Modiano M, Lee K, Mao J, Marini A, Savaraj N, Plezia P,
12
13
Savaraj - 13
Almassian B, Colacino E, Fisher J, and Mc Donald S. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother and Pharmacol.50(3):223-9, 2002.
112. Feun L, Savaraj N, Hurley J, Marini A. Phase II trial of Paclitaxel and Dacarbazine with filgrastim administration in advanced malignant melanoma Cancer Invest. 20(3):357-61, 2002.
113. Liu H, Savaraj N, Priebe W, Lampidis TJ. Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy(ModelC).Biochem Pharmacol. 2002 Dec 15;64(12):1745-51.
114. He L, Chang HX, Chou TC, Savaraj N, Cheng CC. Design of antineoplastic agents based on the '2-phenylnaphthalene-type' structural pattern-synthesis and biological activity studies of 11H-indolo[3.2-c] quinoline derivatives. Eur. J Med Chem. 2003 Jan;38(1):101-7.
115. Feun LG, O’Brian C, Molina E, Rodriguez M, Jeffers L, Schiff ER. Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial. J Cancer Res Clin Oncol. 2003 Jan;129(1):17-20.
116. Savaraj N, Wu CJ, Wangpaichitr M, Kuo MT, Lampidis T, Robles C, Furst AJ, Feun L. Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: Collateral sensitivity to azidothymidine. Int. J. of Oncol. 23(1):173-9, 2003.
117. Robles C, Furst AJ, Sriratana P, Lai S, Chua L, Donnelly E, Solomon J, Sundaram M, Feun L, Savaraj N. Phase II study of vinorelbine with low dose prednisone in the treatment of hormone refractory metastatic prostate cancer. Oncol. Rep.10(4):885-9, 2003
118. Hu YP, Haq B, Carraway KL, Savaraj N, Lampidis TJ.: Multidrug resistance correlates with overexpression of Muc4 but inversely with P-glycoprotein and multidrug resistance related protein in transfected human melanoma cells. Biochem Pharmacol. May 1;65(9):1419-25, 2003.
119. Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T. Phase I and Pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors Clin Cancer Res. 15:9(11) 4092-100, 2003.
120. Wangpaichitr M, Landy H, Wu CJ, Feun LG, Xu R, and Savaraj N. Procollagen-like protein as a molecular target in the treatment
13
14
Savaraj - 14
of primary tumor. Scientific World Journal Jan 2:2 125-6 2002.
121. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF De Young LR, and Lampidis TJ. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancer in vivo. Cancer Res. 164(1) 31-4 2004.
122. Landy H, Markoe A, Potter P, Lasalle G, Marini A, Savaraj N, Keis I, Hero D, Wangpaichitr M, and Feun L. Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma J. Neurooncol. 67:215-20. 2004.
123. Song IS, Savaraj N, Siddik Z, Liu P, Wei YG, Wu CJ, and Kuo MT. Role of copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and resistant cells. Mol. Cancer. Ther.3:1543-9. 2005.
124. Maher JC. Savaraj N, Priebe W, Liu H, Lampidis TJ. Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlate with GLUT-1 expression Pancreas 30:e34-9 2005.
125. Feun L, Marini A, Moffat F, Savaraj N, Hurley J and Mazumder A. Cyclosporin A, alpha-interferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin and tamoxifen: a phase II study in advanced melanoma. Cancer Invest. 23:3-8, 2005.
126. Savaraj N, Wu, CJ, Landy H, Wangpaichitr M, Wei YJ, KuO MT, Robles C, Furst AJ, Lampidis TJ, and Feun L. Procollagen alpha 1 type I. A potential Aide in Histopathological Grading of Glioma. Cancer invest. 23(7),577-81,2005
127. Savaraj N, Wei YG, Liu P, Wu CJ, Wangpaichitr M, Xia D, Xu HJ, Hu SX and Kuo MT. Redox Regulation of Matrix Metalloproteinase Gene Family in Small Cell Lung Cancer Cell Free Radical Res. 39(4): 373-381, 2005
128. Wu CJ, Wangpaichitr M, Feun LG, Kuo MT, Robles C, Lampidis TJ, and Savaraj N. Overcoming cisplatin resistance by mTOR inhibitor. Mol Cancer. 2005 Jul 20;4(1):25-35
129.Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Mclucci MT, Ensor CM, Prestayko AW, Holtsberg Fw, Bomalaski Js, Savaraj N, Feun LG and Logan TF. Pegylated arginine deiminase treatment of patients with metastaic melanoma: results from phase I and II studies J.Clin. Oncol.20:23(30: 7660-8. 2005.
130.Kuo MT, Wei YG, Yang X, Tatebe S, Liu J, Troncoso P, Sahin A, Ro JY, Hamilton SR, and Savaraj N. Association of Fragile Site-Associated(FSA) gene Expression with Epithelial Differentiation
14
15
Savaraj - 15
and Tumor Development. Biochem.Biophy.Res.Com. 340:887-93 , 2005.
131.Wei JG, Lin-Lee YC, Yang X, Dai W, Zhao S, Rassool FV, Elgart GW, Feun L, Savaraj N, and Kuo MT. Molecular Cloning, of chinese hamster 1q31 Chromosomal Fragile Site DNA that is important to mdr1 Gene Amplification Reveals a Novel Gene whose expression is associated with Spermatocytes and Adipocytes differentiation. GENE372:44-52. 2006.
132.Tien Kuo M, Savaraj N. Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers. Mol Carcinog 2006, May 1;45(9) 701-9.
133.Feun L. Savaraj N. Pegylated arginine deiminase: A novel anticancer enztme agent. Expert. Opin. Investig. Drug. 159&) 812-22
134.Feun LG. Marini A. Landy H Markoe A Heros D Robles C. Herrera C and Savaraj N. Clinical trila of CPT-11 and VM26/VP-16 for patient with recurrent brain tumor J. Neurooncol. 82(2) 177-81 2006.
135. Maher JC, Wangpaichitr M. Savaraj N. Kurtoglu and Lampidis TJ. Hypoxia inducuble factor 1 confers resistance to the glycolytic inhibitor 2 deoxy-D Glucose Mol. Cancer Ther. 6(2) 732-41 2007.
136.Kuo MT. Chen HH. Song IS Savaraj N. and Ishikava. The role of copper transporter in cisplatin Resistance Cancer Metastasis Rev. 26(1) 71-83. 2007.
137.Savaraj N, Wu CJ, Kuo MT, You M, Wangpaichitr M, Robles C, Spector M. and Feun L. The relationship of Arginine Deprivation, Argininosuccinate Synthetase and Cell Death in Melanoma. Drug Target Insight 2:119-128 2007.
138.Vy Dinh, Feun L, Elgart G. and Savaraj, N. Merkel Cell Carcinoma. Hematology Clinics of North America. 2: 527-544. 2007.
139.Kurtoglu M, Gao N, Shang J, Maher JJC, Lehman MA, Wangpaichitr M, Savaraj N, Lane AN. Under normoxia, 2-deoxy-D-glucose elicit cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation Mol. Cancer Ther. 6911) 3-49-58. 2007.
140.Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, and Savaraj N. Arginine Deprivation as a Targeted Therapy for Cancer. Curr. Pharma. Design 14(11):1049-57, 2008.
141.Feun L, Savaraj N. Topoisomerase I inhibitors for the treatment of brain tumor Exp. Rev. Anticancer Ther. 8(3) 707-16, 2008.
142 Wangpaichitr M. Savaraj N, Maher J, Kurtoglu and Lampidis TJ. Intrinsically lower AKT, mTOR and HIF activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines. Mol. Cancer. Ther. 7(6):1506-13, 2008
143 Wangpaichitr M, Wu CJ, You M, Kuo MT, Feun L, Lampidis TJ, and Savaraj. Inhibition of mTOR restores cisplatin sensitivity through down regulation of growth and antiapoptotic protein. Eur.J.Pharmacol 59(1-3)124-7
144. Chen HH, Song IS, Hossain A, Choi MK, Tamane Y, Liang ZD, Lu J, Wu LY, Siddik Z, Klomp LW, Savaraj N and Kuo MT. Elevated Glutathione Levels Confers Cellular Sensitization to Cisplatin Toxicity by Upregulation of Copper Transport hCtr. Mol. Pharmacol. 74(3):697-704, 2008
145. Liang ZD, Stockton D, savaraj N, Kuo MT. Mechanistic Comparison of Human Copper Transporter hCtr1-Mediated transports between Copper Ion and Cisplatin. Mol Pharmacol. 2009 Oct;76(4):843-53. Epub 2009
146. Tsai W-B, Aiba I, Lee S-Y, Feun L, Savaraj N, Kuo MT. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1α/Sp4. Mol. Cancer. Ther., 2009: 3223-33.
147. Wangpaichitr M, Wu C, You M, Maher JC, Feun LG, Savaraj. N. N′1,N′3-Dimethyl-N′1,N′3-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS). Cancers, (1), 2009:23-28
148.You M, Savaraj N, Wangpaichitr M, Wu C, Kuo M.T, Varona-Santos J, Nguyen D, Feun L. The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines. Biochem Biophys Res Commun, 394(3)2010:760-6
149. Xi H, Kurtoglu M, Liu H, Wangpaichitr M, You M, Liu X, Savaraj N, Lampidis TJ. 2-Deoxy-D-glucose activates autophagy via ER stress rather than ATP depletion. Cancer Chemother Pharmacol, (Epub ahead of print), Jul-1; 2010
150. Savaraj N, You Min, Wu C.J., Wangpaichitr M, Kuo M.T., Feun L.G. Arginine deprivation, Autophagy, Apoptosis (AAA) for the treatment of Melanoma. Curr Mol Med, 10(4):405-412; 2010
151. Kuo MT, Savaraj N, Feun LG. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Onco. Target, 2010
16
17
Savaraj - 17
152. Wangpaichitr M, Theodoropoulos G, Wu C, You M, Feun LG, Kuo M.T., Savaraj N. The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells. Mol Cancer Ther, 11:604-615; 2012
153. Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rodgers S.E., Wu C.J., You M, Wangpaichitr M, Kuo M.T., Sisson W, Jungbluth A.A., Bomalaski J, Savaraj N. Negativeargininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer; 2012
154. Liang ZD, Tsai WB, Lee MY, Savaraj N, Kuo MT. Specificity protein 1 (sp1) oscillation is involved in copper homeostasis maintenance by regulating human high-affinity copper transporter 1 expression. Mol Pharmacol, 1:455-64; 2012
155. Tsai WB, Aiba I, Long Y, Lin HK, Feun L, Savaraj N, Kuo M.T. Activation of Ras/PI3K/ERK Pathway Induces c-Myc Stabilization to Upregulate Argininosuccinate Synthetase, Leading to Arginine Deiminase Resistance in Melanoma Cells. Cancer Res (Epub ahead of printing); 2012
156. Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N, Kuo MT. Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol Cancer Ther, Nov(11):2483-94; 2012
157. Kuo MT, Fu S, Savaraj N, Chen HH. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res, Sep 15;72(18):4616-21; 2012
158. You M, Savaraj N, Kuo MT, Wangpaichitr M, Varona-Santos J, Wu C, Nguyen DM, Feun L. TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation. Mol Cell Biochem, Nov 11(1-2), 181-90; 2013.
159. Long Y, Tsai WB, Wangpaichitr M, Tsukamoto T, Savaraj N, Feun LG, Kuo MT. Arginine Deiminase Resistance in Melanoma Cells Is Associated with Metabolic Reprogramming, Glucose Dependence and Glutamine Addiction, Mol Cancer Ther. 2013 Aug 29.
160. You M, Varona-Santos J, Singh S, Robbins DJ, Savaraj N, Nguyen DM. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg, Jan;147(1):508-16; 2014.
161. Liang ZD, Long Y, Chen HH, Savaraj N, Kuo MT. Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals. J Biol Inorg Chem; 2014
17
18
Savaraj - 18
162.Matsangou M, Santos ES, RaezL, Gomwz JE, Dinh V, and Savaraj N. Early stage non-small cell lung cancer , role of adjuvant chemotherapy and promising modalities to improve prognosis and survival outcome Future Medicine 3(1) 1-15 2014.
163. Savaraj N, Wu CJ, Li YY, Wangpaichitr M, You M, Bomalaski JS, He W, Kuo MT, Feun LG. Targeting Argininosuccinate Synthetase Negative Melanomas Using Combination of Arginine Degrading Enzyme and Cisplatin, Mol Cancer Ther. 2014 (Accepted with Minor Revision)
164. Wangpaichitr M, Wu CJ, Bigford G, Theodoropoulos G, You M, Li YY, Verona-Santos j, Feun LG, Nguyen DM, Savaraj N.Combination of arginine deprivation with TRAIL treatment as a targeted therapy for mesothelioma. Anticancer Research. 2014 (In press)
Books and Book Chapters:
Loo TL, Savaraj N, Lu K, Yap BS, Yap HY, and Benjamin RS: Clinical pharmacokinetics of Vindesine. Periti P, Grasser GG (Eds). Current Chemotherapy and Immunotherapy, pp ll407-l409. Proc of the l2th International Congress of Chemotherapy, Florence, Italy, July, l98l.
Lu K, Savaraj N, and Loo TL: Pharmacokinetic studies of l,4-Dihydroxy-5,8-Bis (2-(2-Hydroxyethyl)amino)ethyl)Amino-9,l0-Anthracenedion (DHAD, NSC-279836). Rozencweig M, Von Hoff DD, Shaquet M (eds). New Anticancer Drugs: Mitoxantone and Bisantrene, Raven Press, NY, l982.
Feun LG, Lee Y-Y, Wallace S, Charnsangavej C, Savaraj N, Carrasco CH, Gianturco C, and Yung WKA: New drugs and delivery techniques. In: Progress in Experimental Tumor Research. Vopl. 29:l3l-l39 (Karger, Bosel), l985.
Lampidis TJ, Savaraj N, Valet G, Fourcade A, and Tapeiro H: Relationship of chemical change of anticancer agents to drug accumulation and cytotoxicity in cadaver and tumor cells: Relevance to multidrug resistance. John Libbey Publisher, London Vol 169:655-660, 1990.
Feun L, Kuo MT, Wu C, Wangpaichitr M, and Savaraj N. Arginine Deiminase and Cancer Therapy. In: Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools. John Wiley Publishers, Chapter 9; 2010
Savaraj N, You M, Wu CJ, Kuo MT, Dinh V, Wangpaichitr M, and Feun, LG. Targeting Argininosuccinate Synthetase in Cancer Therapy. In: Cell Signaling & Molecular Target in Cancer, Springer Science
18
19
Savaraj - 19
Publishers, Chapter 3; 2011
Savaraj N, You M, Chunjing W, Kuo MT, Dinh V, Wangpaichitr M and Feun L. Targeting argininosuccinate synthetase in Cancer Therapy In: Cell Signalling and Molecular Targets in Cancer. Springer 2012 pp37-52
Feun L, Wangpaichitr M, Wu CJ, Li JJ, You M, Kuo MT, Tsai W-B, Long Y, Savaraj N. Arginine in Cancer Therapy. In: Arginine in Clinical Nutrition . John Wiley and Sons, Inc , 2014 (in press).
V. PROFESSIONAL a. GRANTS RECEIVED WITHIN THE PAST FIVE YEARS
V.A. Healthcare System
Mentor: Dept. of Veterans Affairs; Career Development Award2: Metabolic Reprogramming: A New Paradigm for Targeting Cisplatin Resistant Cells. (P.I.) Dr. Medhi Wangpaichitr 2012-2017. $800,000
Woman Cancer Association
PI: Selectively Kill KRAS Mutation Non Small Cell Lung Cancer by Exploiting ROS and Metabolic Differences 2014-2015. $50,000
State of Florida (James and Esther King)
Mentor: Florida Department of Health, Postdoc Award: Targeting ROS and Tumor Metabolism to Selectively Kill Cisplatin Resistant Lung Cancer. (P.I.) Dr.Medhi Wangpaichitr 2010-2013. $165,000
19
20
Savaraj - 20
NIH Partnering-PI (RO1): Mechanism of Resistance to Arginine
Deiminase Therapy in Advance Melanoma. (Partner-PI) Dr. M.T. Kuo 2010-2015, $200,000
Co-PI (RO1) Improving the Efficacy of Cisplatin-Based Cancer Chemotherapy (P.I) Dr. M.T. Kuo 2010-2015
Site-PI (Multi-center Award): Validation of Multi-Gene Test for Lung Cancer Rish: (LCRT) Protocol, Sponsor by University of Toledo; 2011-2014
Department of Defense
PI, Profiling metabolic rewiring in serum as markers to detect drug resistance in lung cancer, 2014. ($200,000 Pending)
P.I. VA Merit Review: Overcoming Cisplatin Resistance by Inhibiting mTOR Oct. 2005-2009 total amount 483,200.
Recipient of VA merit review award since 1990.
NIH Co PI: NIH (R01) Arginine Deprivation: A targeted therapy for
malignant melanoma total amount $450,000 from 2004-2008. (P.I.) Dr. Lynn G Feun.
Co-Investigator: NIH (R01) Redox regulation of multidrug resistant gene expression (P.I.) Dr. Marcus Tien Kuo Department of Molecular Pathology, M.D. Anderson Cancer Center. 2006-2012. $ 650,000 total
Collaborator: NIH (R01) Antitumor Activity of Sugar Analogs via Blocking Glycolysis VS Glycosylation. (P.I.) Dr. T. Lampidis. 2007-2011.
Pharmaceutical Company
Determining argininosuccinate synthetase (ASS) expression in melanoma patients treated with arginine depleting therapy. Polaris Pharmaceutical Total amount $50,000.
20
21
Savaraj - 21
A Randomized Open Label Multi-Center Study of XRP6258 at 25 mg/m2 in Combination with Prednisone Every 3 weeks Compared to Mitoxantrone in Combination with prednisone for the treatment of Hormone Refrcatory Metastatic Prostate Cancer Previously Treated with a Taxotere Containing Regimen Total amount $60,000.
Phase I-II trial of SOM230 (Pansireotide) in hepatoma Novartis (Clinical with laboratory correlation). Total amount $200,000
Phase I-II trial of SOM230(Pansireotide) in Small Cell Lung Cancer Novartis (Clinical with laboratory correlation). Total amount $200,000
Phase I-II trial of combination of Irinotecan and Pansireotide(SOM230)for recurrent/second line therapy in small cell lung cancer. (NovartiS) (clinical with laboratory correlation)
American Cancer Society Correlation of Unique 220 Kda protein with vitaminD sensitivity In primary brain tumor $25,000 (mentor for Dr. C.J. Wu).
2002 – 2004 Circumvention of Drug Resistance in Small Cell Lung Cancer Using Flavopiridol. $35,000 Adventis.
2002 – 2004 Phase II study of combination of Docetaxel and celecoxib in hormonal refractory prostate cancer. (Mentor for Dr.Carlos Robles) $80,000 (Pharmacia and Aventis)
2001 - 2003 Phase II Study of Celecoxib, Irinotecan, 5FU and LCV in Patients with Advanced Colorectal cancer
2000 – 2001 Procrit VS No Procrit in Outcomes of hormonal Refractory Prostate cancer OrthoBiotec. $10,000
2000 - 2001 Phase II study of Cetuximab (Monoclonal antibody C-225) in combination with irinotecan in relapsed colon cancer.
1997 – 2000 NIH, $106,000 per yearProbing MRP and MDR Resistance”, Co-Investigator 10% Effort. P.I.: T.J. Lampidis, M.D.
1997 – 2000 Bayer, A Randomized, Multicenter, Double-Blind,
21
22
Savaraj - 22
Placebo-Controlled Study Comparing Single-Agent BAY 12-9566 to Matched Placebo in patients with Small Cell Lung Cancer (SCLC) in Complete Remission, $30,000
1997 – 2000 Bayer, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Evaluation of BAY-12-9566 in Patients with Stage IIIA or IIIB Non Small Cell Lung Cancer, $30,000
1997 – 2000 SmithKline Beecham, Phase II Trial of Sequential Treatment of Topotecan and Etoposide in High and Intermediate Grade Lymphoma, $30,000
1997 – 2000 GlaxoWellcome, Phase II study of Navelbine with low dose prednisone in the treatment of hormonal refractory metastatic prostate cancer, $20,000
1997 - 2000 Maxim Pharmaceuticals, Multi-Center, Randomized Open-Label Study to Evaluate the Safety and Efficacy of Combined Immunotherapy with Subcutaneous Interleukin-2, and Histamine Dihydrochloride Versus Subcutaneous Interkeukin-2 Alone in Patients with Advanced Malignant Melanoma, $30,000
1997 – 2000 Bristol-Myers Squibb, A Phase II Trial of Paclitaxel (Taxol) Administered as a Weekly One Hour Infusion in Previously Treated Patients with Advanced Head and Neck Cancer, $30,000
1998 - 1999 Vion Pharmaceuticals, Phase I and Pharmacokinetic Study of 3AP.
b. Professional and Honorary Organization
Past member of study section in Cancer Biology and Immunology NCI and NIH (1991-1995).
Ad Hoc Member of RAG review for V.A.M.C.
Ad hoc Member of ET-1 study section NCI, NIH. 2002-2003
Past member of Molecular Pharmacology and Drug Design Study Section NIH from 2003-2007
Ad Hoc Members of Special Study Section Cancer Biomarker and Therapeutics NCI, NIH.
22
23
Savaraj - 23
Ad-Hoc Member of the spore grant review
Member of SBIR drug design
Reviews for Biochemistry and American Journal of Clinical Oncology.
Blaffer Award Lecture “Targeting Therapy for Melanoma” M.D. Anderson Cancer Center April 2006
Special Contribution Award from Department of Veteran Affair For the excellent and commitment for the care of veteran.
Special Contribution Award from Department of Veteran Affair. JCAHO survey has mentioned on the survey for the excellent care we provide in Oncology service
Special Contribution Award from Department of Veteran affair for Research service. (Human subject and protocol review.
Recipient of Special Contribution Award for her leadership and commitment to the care of veterans from V.A. Health Care System.
Recipient of Special Contribution Award for her significant contribution in Oncology section at V.A. which reflected in JCAHO report.
Recipient of Special Contribution Award for her contribution in the field of research and development at V.A.
Member of NIH SBIR drug discovery study section 2009-presence
Member of NIH Broad Challenge grant 2009
Member of NIH reviewer for Loan Repayment Program 2010-presence
Member of Therapeutic Drug Discovery Review (NCATS) 2012
c. POST DOCTORAL TRAINING
7/73 - 6/74 Internship, St. Vincent's Medical Center, Bridgeport, CT7/74 - 6/76 Residency, St. Vincent's Medical Center, Bridgeport, CT
7/76 - 6/78 Oncology Fellow, University of Miami 7/78 - l2/78 Hematology Fellow, Medical College of Georgia
1/79 - l2/79 Hematology Fellow, University of Miami
d. OTHER PROFESSIONAL ACTIVITIES
23
24
Savaraj - 24
Member of the American Association for Cancer ResearchMember of the American Society of Clinical Oncology
e. SCIENTIFIC PRESENTATIONS
American Association of Cancer Research every year since 1979.Multiple presentation in American Society of Clinical Oncology.
f. PATENT
Co-patent on a series of topoisomerase I & II inhibitor compounds with Dr. C.C. Cheng from University of Kansas.
VI.TEACHING 1. Teaching Rounds with Fellows. House staff 2. Co-adviser for graduate student: Department of Molecular Cell
BiologyGraduate student’s name Dr. John Maher and Dr. Medhi Wangpaichitr. Current graduate student: Mr. Hai bin, Ms. Katherine Philips. Ms. Elizabeth Sullivan
3. Graduate student class: Cancer Biology and metabolism. 4. Fellow class: Signal transduction and cell death. 5. Post-doctoral fellow Dr. Jiang Ying Zou 1999-2000.6. Post-doctoral fellow Dr. 2000-2001 Dr. Y.H. Zhang 7. Post doctoral fellow Dr. You Min 2007-present8. Post-doctoral fellow Dr. Medhi Wangpaichitr 2008-2011
VII. SERVICE
DEPARTMENTAL ADMINISTRATIVE AND COMMITTEE RESPONSIBILITIES Member of the grant reviewer: American Cancer Society institutional grant 2002-present
Member of the grant reviewer: Sylvester Comprehensive Cancer Center, 2001-2002
EXTRA-DEPARTMENTAL ADMINISTRATIVE AND COMMITTEE RESPONSIBILITIES
1990 - 1991 Chairman, Human Studies Committee, VA Medical Center, Miami, FL.
1989 - 1991 Research & Development Committee, VA Medical Center, Miami, FL.
24
25
Savaraj - 25
1989 - 1990 Animal Subcommittee, VA Medical Center, Miami, FL.
1988 - 1991 Human Studies Subcommittee, Research & Development Committee, VA Medical Center, Miami, FL.
1987 - 1989 Equipment Subcommittee, Research & Development Committee, VA Medical Center, Miami, FL.
1986 - 1995 Radioisotope Committee, University of Miami, Miami, FL.
1993 - 1994 Chairman, Space Committee, V.A. Medical Center, Miami, FL.
1996- 1997 Chairman, Human Subjects Committee, VA Medical Center.
1998 – 1999 Member, Budget Subcommittee, VA Medical Center, Miami, FL.
1998 – 1999 Member, Space Committee, VA Medical Center, Miami, FL.
1999 – 2003 Member, Equipment Subcommitte, VA Medical Center, Miami, FL.
1999 – 2003 Member, Biohazard Safety Subcommittee, VA Medical Center, Miami, FL.
2000 – 2001 member Human Subjects Committee, VA Medical Center, Miami, FL.
2002- 2006 Alt. member of Human Subject committee. VAMC.
2007- Member of Human Subject committee. VAMC2007- Ad-hoc Member of R&D committee VAMC2008- Member of the Promotion and tenure committee
